Targeting airway inflammation in asthma: Current and future therapies

Chest

Volumn 133, Issue 4, 2008, Pages 989-998

  Hanania, Nicola A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Airway inflammation; Antiinflammatory therapy; Asthma; IgE; Inhaled corticosteroids; Omalizumab; Steroid resistant asthma

Indexed keywords

ADENOSINE; ANTIALLERGIC AGENT; BCG VACCINE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE PLUS FORMOTEROL; CHEMOKINE RECEPTOR CCR2; CICLESONIDE; CLARITHROMYCIN; CORTICOSTEROID; CVT 6883; ENDOTHELIN DERIVATIVE; ETANERCEPT; HISTAMINE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 9; LEUKOTRIENE; MITOGEN ACTIVATED PROTEIN KINASE P38; NITRIC OXIDE; OMALIZUMAB; PROSTAGLANDIN DERIVATIVE; PROTEIN KINASE SYK; STRESS ACTIVATED PROTEIN KINASE; TELITHROMYCIN; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR NFAT; TRYPTASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERY LATE ACTIVATION ANTIGEN 4; ZILEUTON;

ASTHMA; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; DRUG TARGETING; EOSINOPHIL; HUMAN; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT INFLAMMATION; REVIEW; TH2 CELL;

EID: 42149196003     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.07-0829     Document Type: Article

References (89)

1. Bousquet J, Jeffery PK, Busse WW, et al. Asthma: from bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med 2000; 161:1720-1745
2. Barnes PJ. New drugs for asthma. Nat Rev Drug Discov 2004; 3:831-844
3. Green RH, Brightling CE, Mckenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomized controlled trial. Lancet 2002; 360:1715-1721
4. Sont JK, Willems LNA, Bel EH, et al. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. Am J Respir Crit Care Med 1999; 159:1043-1051
5. National Asthma Education and Prevention Program. Expert panel report 2: guidelines for the diagnosis and management of asthma; update on selected topics 2002. Bethesda, MD: National Heart, Lung, and Blood Institute, National Institutes of Health, 2003; NIH Publication No. 02-5047
6. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL Study. Am J Respir Crit Care Med 2004; 170:836-844
7. Adcock IM, Ito K, Barnes PJ. Glucocorticoids: effects on gene transcription. Proc Am Thorac Soc 2004; 1:247-254
8. van Rensen ELJ, Straathof KCM, Veselic-Charvat MA, et al. Effect of inhaled steroids on airway hyperresponsiveness, sputum eosinophils, and exhaled nitric oxide levels in patients with asthma. Thorax 1999; 54:403-408
9. Djukanovic R, Wilson JW, Britten KM, et al. Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am Rev Respir Dis 1992; 145:669-674
10. 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial. J Allergy Clin Immunol 1992; 90:32-42
11. Olivieri D, Chetta A, Del Donno M, et al. Effect of short-term treatment with low-dose inhaled fluticasone propionate on airway inflammation and remodeling in mild asthma: a placebo-controlled study. Am J Respir Crit Care Med 1997; 155:1864-1871
12. 2-agonists and corticosteroids. Eur Respir J 2002; 19:182-191
13. Salpeter SR, Buckley NS, Ormiston TM, et al. Meta-analysis: effect of long-acting β-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med 2006; 144:904-912
14. Nelson HS, Weiss ST, Bleecker ER, et al. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129:15-26
15. 2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma. Cochrane Database Syst Rev (database online). Issue 4, 2005
16. Israel E, Chinchilli VM, Ford JG, et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 2004; 364:1505-1512
17. Wechsler ME, Lehman E, Lazarus SC, et al. National Heart, Lung, and Blood Institute's Asthma Clinical Research Network β-adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med 2006; 173:519-526
18. 2-adrenergic receptor genotype in subjects with persistent asthma. J Allergy Clin Immunol 2006; 118:809-816
19. Horwitz RJ, McGill KA, Busse WW. The role of leukotriene modifiers in the treatment of asthma. Am J Respir Crit Care Med 1998; 157:1363-1371
20. Maeba S, Ichiyama T, Ueno Y, et al. Effect of montelukast on nuclear factor κB activation and proinflammatory molecules. Ann Allergy Asthma Immunol 2005; 94:670-674
21. Can M, Yuksel B, Demirtas S, et al. The effect of montelukast on soluble interleukin-2 receptor and tumor necrosis factor alpha in pediatric patients. Allergy Asthma Proc 2006; 27:383-386
22. Langlois A, Ferland C, Tremblay GM, et al. Montelukast regulates eosinophil protease activity through a leukotriene-independent mechanism. J Allergy Clin Immunol 2006; 118:113-119
23. National Asthma Education and Prevention Program. Expert panel report 3: guidelines for the diagnosis and management of asthma; summary report 2007. J Allergy Clin Immunol 2007; 120(suppl);S44-S138
24. American Lung Association Asthma Clinical Research Centers. Clinical trial of low-dose theophylline and montelukast in patients with poorly controlled asthma. Am J Respir Crit Care Med 2007; 175:235-242
25. Berger W, De Chandt MT, Cairns CB. Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease. Int J Clin Pract 2007; 61:663-676
26. O'Connor BJ, Lofdahl CG, Balter M, et al. Zileuton added to low-dose inhaled beclomethasone for the treatment of moderate to severe persistent asthma. Respir Med 2007; 101:1088-1096
27. Barnes PJ. Theophylline: new perspectives for an old drug. Am J Respir Crit Care Med 2003; 167:813-818
28. Szefler SJ, Martin RJ, King TS, et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol 2002; 109:410-418
29. Federico MJ, Covar RA, Brown EE, et al. Racial differences in T-lymphocyte response to glucocorticoids. Chest 2005; 127:571-578
30. Peters-Golden M, Swern A, Bird SS, et al. Influence of body mass index on the response to asthma controller agents. Eur Respir J 2006; 27:495-503
31. Barnes PJ. Corticosteroids: the drugs to beat. Eur J Pharmacol 2006; 533:2-14
32. Wenzel SE, Schwartz LB, Langmack EL, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999; 160:1001-1008
33. Holgate ST, Polosa R. The mechanisms, diagnosis, and management of severe asthma in adults. Lancet 2006; 368:780-793
34. ten Brinke A, Zwinderman AH, Sterk PJ, et al. "Refractory" eosinophilic airway inflammation in severe asthma: effect of parenteral corticosteroids. Am J Respir Crit Care Med 2004; 170:601-605
35. Niven AS, Argyros G. Alternate treatments in asthma. Chest 2003; 123:1254-1265
36. Bradding P, Walls AF, Holgate ST. The role of the mast cell in the pathophysiology of asthma. J Allergy Clin Immunol 2006; 117:1277-1284
37. Platts-Mills TAE. The role of immunoglobulin E in allergy and asthma. Am J Respir Crit Care Med 2001; 164:S1-S5
38. Burrows B, Martinez FD, Halonen M, et al. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med 1989; 320:271-277
39. Sears MR, Burrows B, Flannery EM, et al. Relation between airway responsiveness and serum IgE in children with asthma and in apparently normal children. N Engl J Med 1991; 325:1067-1071
40. Sherrill DL, Stein R, Halonen M, et al. Total serum IgE and its association with asthma symptoms and allergic sensitization among children. J Allergy Clin Immunol 1999; 104:28-36
41. Kerkhof M, Dubois AEJ, Postma DS, et al. Role and interpretation of total serum IgE measurements in the diagnosis of allergic airway disease in adults. Allergy 2003; 58:905-911
42. Soresi S, Togias A. Mechanisms of action of antiimmunoglobulin E therapy. Allergy Asthma Proc 2006; 27:S15-S23
43. Beck LA, Marcotte GV, MacGlashan D, et al. Omalizumab-induced reductions in mast cell FcεRI expression and function. J Allergy Clin Immunol 2004; 114:527-530
44. Prussin C, Griffith DT, Boesel KM, et al. Omalizumab treatment downregulates dentritic cell FcεRI expression. J Allergy Clin Immunol 2003; 112:1147-1154
45. Fahy JV, Fleming HE, Wong HH, et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997; 155:1828-1834
46. Noga O, Hanf G, Brachmann I, et al. Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. J Allergy Clin Immunol 2006; 117:1493-1499
47. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108:184-190
48. Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18:254-261
49. Bousquet J, Cabrera P, Berkman N, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005; 60:302-308
50. Niebauer K, Dewilde S, Fox-Rushby J, et al. Impact of omalizumab on quality-of-life outcomes in patients with moderate-to-severe allergic asthma. Ann Allergy Asthma Immunol 2006; 96:316-326
51. Bousquet J, Wenzel S, Holgate S, et al. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest 2004; 125:1378-1386
52. Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60:309-316
53. Oba Y, Salzman GA. Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma. J Allergy Clin Immunol 2004; 114:265-269
54. Gendo K, Lodewick MJ. Asthma economics: focusing on therapies that improve costly outcomes. Curr Opin Pulm Med 2005; 11:43-50
55. Renauld J-C. New insights into the role of cytokines in asthma. J Clin Pathol 2001; 54:577-589
56. Borish LC, Nelson HS, Lanz MJ, et al. Interleukin-4 receptor in moderate atopic asthma: a phase I/II randomized, placebo-controlled trial. Am J Respir Crit Care Med 1999; 160:1816-1823
57. Borish LC, Nelson HS, Corren J, et al. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol 2001; 107:963-970
58. Leckie MJ, ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000; 356:2144-2148
59. Flood-Page PT, Menzies-Gow AN, Kay AB, et al. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 2003; 167:199-204
60. Flood-Page P, Menzies-Gow A, Phipps S, et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 2003; 112:1029-1036
61. Kips JC, O'Connor BJ, Langley SJ, et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med 2003; 167:1655-1659
62. Tamaoki J, Kondo M, Sakai N, et al. Effect of suplatast tosilate, a Th2 cytokine inhibitor, on steroid-dependent asthma: a double-blind randomized study. Lancet 2000; 356:273-278
63. Sano Y, Suzuki N, Yamada H, et al. Effects of suplatast tosilate on allergic eosinophilic airway inflammation in patients with mild asthma. J Allergy Clin Immunol 2003; 111:958-966
64. Howarth PH, Babu KS, Arshad HS, et al. Tumor necrosis factor (TNFα) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 2005; 60:1012-1018
65. Berry MA, Hargadon B, Shelley M, et al. Evidence of a role of necrosis factor α in refractory asthma. N Engl J Med 2006; 354:697-708
66. Erin EM, Leaker BR, Nicholson GC, et al. The effects of a monoclonal antibody directed against tumor necrosis factor-α in asthma. Am J Respir Crit Care Med 2006; 174:753-762
67. van Schalkwyk E, Strydom K, Williams Z, et al. Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions. J Allergy Clin Immunol 2005; 116:292-298
68. Bousquet J, Aubier M, Sastre J, et al. Comparison of roflumilast, an oral anti-inflammatory, with beclomethasone dipropionate in the treatment of persistent asthma. Allergy 2006; 61:72-78
69. Bateman ED, Izquierdo JL, Harnest U, et al. Efficacy and safety of roflumilast in the treatment of asthma. Ann Allergy Asthma Immunol 2006; 96:679-686
70. Deng YM, Xie QM, Tang HF, et al. Effects of ciclamilast, a new PDE 4 PDE4 inhibitor, on airway hyperresponsiveness, PDE4D expression and airway inflammation in a murine model of asthma. Eur J Pharmacol 2006; 547:125-135
71. Garey KW, Rubinstein I, Gotfried MH, et al. Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma. Chest 2000; 118:1826-1827
72. Johnston SL, Blasi F, Black PN, et al. The effect of telithromycin in acute exacerbations of asthma. N Engl J Med 2006; 354:1589-1600
73. O'Byrne PM, Bisgaard H, Godard PP, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005; 171:129-136
74. Rabe KF, Pizzichini E, Stallberg B, et al. Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial. Chest 2006; 129:246-256
75. Rabe KF, Atienza T, Magyar P, et al. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet 2006; 368:744-753
76. Humbert M. Ciclesonide: a novel inhaled corticosteroid. Expert Opin Investig Drugs 2004; 13:1349-1360
77. Bateman E, Karpel J, Casale T, et al. Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma. Chest 2006; 129:1176-1187
78. Spicuzza L, Di Maria G, Polosa R. Adenosine in the airways: implications and applications. Eur J Pharmacol 2006; 533:77-88
79. Ryzhov S, Goldstein AE, Matafonov A, et al. Adenosine-activated mast cells induce IgE synthesis by B lymphocytes: an A2B-mediated process involving Th2 cytokines IL-4 and IL-13 with implications for asthma. J Immunol 2004; 172:7726-7733
80. Zhong H, Belardinelli L, Maa T, et al. Synergy between A2B adenosine receptors and hypoxia in activating human lung fibroblasts. Am J Respir Cell Mol Biol 2005; 32:2-8
81. Mustafa SJ, Nadeem A, Fan M, et al. Effect of a specific and selective A2B adenosine receptor antagonist on adenosine agonist AMP and allergen-induced airway responsiveness and cellular influx in a mouse model of asthma. J Pharmacol Exp Ther 2007; 320:1246-1251
82. Smit JJ, Lukacs NW. A closer look at chemokines and their role in asthmatic responses. Eur J Pharmacol 2006; 533:277-288
83. Morokata T, Suzuki K, Masunaga Y, et al. A novel, selective, and orally available antagonist for CC chemokine receptor 3. J Pharmacol Exp Ther 2006; 317:244-250
84. Wegmann M, Goggel R, Sel S, et al. Effects of a low-molecular-weight CCR-3 antagonist on chronic experimental asthma. Am J Respir Cell Mol Biol 2007; 36:61-67
85. Adcock IM, Chung KF, Caramori G, et al. Kinase inhibitors and airway inflammation. Eur J Pharmacol 2006; 533:118-132
86. Rolin S, Masereel B, Dogne JM. Prostanoids as pharmacological targets in COPD and asthma. Eur J Pharmacol 2006; 533:89-100
87. Belvisi MG, Hele DJ, Birrell MA. Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation. Eur J Pharmacol 2006; 533:101-109
88. Redington AE. Modulation of nitric oxide pathways: therapeutic potential in asthma and chronic obstructive pulmonary disease. Eur J Pharmacol 2006; 533:263-276
89. Felseszko W, Jaworska J, Hamelmann E. Toll-like receptors: novel targets in allergic airway disease (probiotics, friends, and relatives). Eur J Pharmacol 2006; 533:308-318